Zhang Tian, Li Ting, Zhao Fei, Li Tongzhou, Zhang Miaomiao, Jin Pengfei
Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing, 100730, PR China.
Heliyon. 2024 Jul 24;10(15):e35081. doi: 10.1016/j.heliyon.2024.e35081. eCollection 2024 Aug 15.
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is responsible for the outbreak of COVID-19 in Wuhan, China. As a highly infectious epidemic, SARS-CoV-2 rapidly evolves. Presently, COVID-19 coexists with humans, mainly with mild or moderate disease. The latest Guidelines for the Diagnosis and Treatment of COVID-19 (trial version of the 10th Edition) recommend several oral traditional Chinese medicines (TCMs) for treatment. This study aims to evaluate the evidence-based benefits of these TCMs as adjunctive therapies to conventional western medicine (CWM) for patients with mild or moderate COVID-19.
We conducted a systematic review and meta-analysis adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, utilizing the PRISMA checklist. We searched PubMed, Cochrane Library, Embase, CNKI, and Wan-Fang databases to retrieve randomized controlled trials and retrospective cohort studies of TCM in combination with CWM on the treatment of mild or moderate COVID-19 that were published as of December 25, 2023. A network meta-analysis using the frequency model was employed to evaluate the benefits of different interventions.
A total of 30 eligible studies, enrolling 4144 participants, utilized 7 marketed oral TCMs in China. Compared with CWM alone, the integration of TCMs with CWM can significantly reduce severe conversion rate. This combined approach also enhances the clinical effective rate, shortens the negative conversion time of nucleic acid, and improves both symptoms and blood biochemical markers in patients. The network meta-analysis provided preliminary evidence of the superiority of specific TCMs for various outcomes: Qingfei Paidu for raising the CT improvement rate and clinical effective rate, and shortening the negative conversion time of nucleic acid; Huashi Baidu for reducing severe conversion and improving cough; Xuanfei Baidu for improving fatigue; Jinhua Qinggan for improving fever; Lianhua Qingwen for shortening the recovery time of fatigue and cough; and Shufeng Jiedu for shortening the recovery time of fever.
TCM in combination with CWM may be beneficial for patients with mild or moderate COVID-19. Each TCM may have distinct benefits in COVID-19.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)导致了中国武汉的新型冠状病毒肺炎(COVID-19)疫情爆发。作为一种高传染性流行病,SARS-CoV-2迅速演变。目前,COVID-19与人类共存,主要表现为轻症或中症。最新的《新型冠状病毒肺炎诊疗方案(试行第十版)》推荐了几种口服中药用于治疗。本研究旨在评估这些中药作为辅助疗法与传统西药(CWM)联合应用于轻症或中症COVID-19患者的循证效益。
我们按照系统评价和Meta分析的首选报告项目(PRISMA)指南,使用PRISMA清单进行了一项系统评价和Meta分析。我们检索了PubMed、Cochrane图书馆、Embase、中国知网和万方数据库,以检索截至2023年12月25日发表的关于中药与CWM联合治疗轻症或中症COVID-19的随机对照试验和回顾性队列研究。采用频率模型进行网络Meta分析,以评估不同干预措施的效益。
共有30项符合条件的研究,纳入4144名参与者,使用了中国7种上市的口服中药。与单纯使用CWM相比,中药与CWM联合应用可显著降低重症转化率。这种联合方法还提高了临床有效率,缩短了核酸转阴时间,并改善了患者的症状和血液生化指标。网络Meta分析提供了特定中药在各种结局方面优越性的初步证据:清肺排毒汤提高CT改善率和临床有效率,并缩短核酸转阴时间;化湿败毒方降低重症转化率并改善咳嗽;宣肺败毒方改善乏力;金花清感方改善发热;连花清瘟缩短乏力和咳嗽恢复时间;疏风解毒胶囊缩短发热恢复时间。
中药与CWM联合应用可能对轻症或中症COVID-19患者有益。每种中药在COVID-19中可能具有不同的效益。